Argentarii LLC Has $380,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Argentarii LLC lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,392 shares of the biopharmaceutical company’s stock after buying an additional 99 shares during the quarter. Argentarii LLC’s holdings in Gilead Sciences were worth $380,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences during the first quarter valued at about $25,000. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences during the 1st quarter worth about $29,000. Annis Gardner Whiting Capital Advisors LLC boosted its stake in Gilead Sciences by 158.8% during the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 216 shares during the period. Core Alternative Capital grew its holdings in Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 241 shares during the last quarter. Finally, Lee Danner & Bass Inc. bought a new position in Gilead Sciences in the 4th quarter worth approximately $41,000. 83.67% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $330,510.00. Following the transaction, the insider directly owned 120,168 shares in the company, valued at approximately $13,238,908.56. This represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Monday, June 30th. The shares were sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the sale, the chief executive officer directly owned 615,725 shares in the company, valued at $68,006,826.25. This trade represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 58,500 shares of company stock worth $6,340,745. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Trading Down 0.2%

Shares of GILD stock opened at $111.28 on Friday. The company has a market capitalization of $138.42 billion, a P/E ratio of 23.43, a P/E/G ratio of 0.72 and a beta of 0.29. Gilead Sciences, Inc. has a 12-month low of $66.34 and a 12-month high of $119.96. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The firm has a 50-day moving average price of $107.02 and a 200 day moving average price of $104.02.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. Gilead Sciences’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.32) earnings per share. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Stockholders of record on Friday, June 13th were issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.84%. The ex-dividend date was Friday, June 13th. Gilead Sciences’s payout ratio is presently 66.53%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on GILD shares. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research report on Thursday, March 27th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price target on the stock. Morgan Stanley upped their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Finally, Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.